Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AMAG Seeks Dialysis And Pre-Dialysis CKD Indication For Ferumoxytol

This article was originally published in The Pink Sheet Daily

Executive Summary

A potential competitor, Luitpold’s Injectafer, is scheduled to go before an FDA advisory committee Feb. 1.

You may also be interested in...



3SBio Sees Strong Growth In Q1 Driven By Oncology Product EPIAO

SHANGHAI - Biotech company 3SBio saw revenues increase 23.7 percent in the first quarter of 2009, driven by the company's leading recombinant human erythropoietin injection EPIAO, the only approved EPO drug in China

3SBio And AMAG Ink Deal To Develop Ferumoxytol In China

Projected U.S. approval triggers Chinese NDA for the anemia drug.

3SBio And AMAG Ink Deal To Develop Ferumoxytol In China

Projected U.S. approval triggers Chinese NDA for the anemia drug.

Related Content

Topics

UsernamePublicRestriction

Register

PS065540

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel